Kornimate/medical-research-clean huggingface dataset:
gleevec in relapsed/refractory t cell non-hodgkin's lymphoma

Conditions: T Cell Non-Hodgkin Lymphoma

Summary: the purpose of this research study is to evaluate the overall response rate to imatinib mesylate in participants with relapsed or refractory t cell non-hodgkin's lymphoma. this drug has been used in chronic myeloid leukemia and information from those other research studies suggests that it may help to treat t cell non-hodgkin's lymphoma.

objectives: primary objective to evaluate the overall response rate secondary objectives to assess the safety and tolerability to assess the duration of response to assess the progression free survival and overall survival statistical design: this trial will use a single stage design to differentiate a \>/= 25% response rate from a \</= 5% rate. if observed data is consistent with the alternative response rate of 25%, imatinib would be deemed clinically interesting and worthy of a larger phase ii study.

Eligibility criteria:
inclusion criteria: * histologically confirmed t nhl, excluding t prolymphocytic leukemia, t lymphoblastic lymphoma, and t/nk large granular lymphocytic leukemia. * measurable disease, defined as at least one bidimensionally measurable site of disease measuring at least 1.5cm in greatest diameter. * failed at least one systemic chemotherapy or biologic therapy for t cell lymphoma unless it can be clearly documented that the patient can not tolerate such therapy. * 18 years of age or older * life expectancy of greater than 3 months * ecog performance status of lesser then or equal to 2 * normal organ and marrow function as outlined in the protocol * agree to the use of adequate contraception prior to study entry and for the duration of the study exclusion criteria: * chemotherapy or radiotherapy within 4 weeks prior to entering the study * receiving any other study agents * cns lymphoma requiring active therapy * history of allergic reactions attributed to compounds of similar chemical or biologic composition to imatinib mesylate * participants requiring concomitant administration of any medications or substances that are inhibitors or inducers of cyp3a4 are ineligible * patient previously received radiotherapy to 25% or greater of the bone marrow * uncontrolled intercurrent illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * pregnant or lactating women * history of a different malignancy except for individuals who have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy * hiv-positive individuals on combination antiretroviral therapy * known chronic liver disease * major surgery within 2 weeks prior to study entry

Keywords: t nhl gleevec imatinib mesylate
study to evaluate the safety and tolerability of krx-0502 (ferric citrate) in children with iron deficiency anemia associated with non-dialysis dependent chronic kidney disease

Conditions: Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease

Summary: this study will be conducted to evaluate the safety and tolerability of ferric citrate in pediatric participants with iron deficiency anemia (ida) associated with non-dialysis dependent chronic kidney disease (ndd-ckd).


Eligibility criteria:
inclusion criteria: * age 6 years to \<18 years at screening * body weight ≥12 kilograms (kg) at screening * chronic kidney disease (ckd) stage 3 to 5, not on dialysis, with estimated glomerular filtration rate (egfr) \<60 milliliters per minute (ml/min)/1.73 meters squared (m\^2) utilizing the "bedside schwartz" equation * hemoglobin (hgb) ≥8.5 and ≤11.5 grams per deciliter (g/dl) at screening * transferrin saturation (tsat) ≤25% at screening * ferritin ≤200 nanograms per milliliter (ng/ml) at screening exclusion criteria: * serum phosphorus level at screening: * 6 to \<13 years: ≤4.0 milligrams per deciliter (mg/dl); * 13 to \<18 years: ≤2.7 mg/dl * liver transaminases (aspartate aminotransferase \[ast\] and/or alanine aminotransferase \[alt\]) ˃3× the upper limit of normal at screening * active significant gastrointestinal (gi) disorder, including overt gastrointestinal (gi) bleeding or active inflammatory bowel disease * unable to swallow pills * anemia due to causes other than iron deficiency anemia (ida) of ckd * intravenous iron therapy or blood transfusion within 4 weeks before the screening visit * participants with a functioning organ transplant * receipt of any investigational drug within 4 weeks before screening * phosphate binder use during the screening period

Keywords: iron deficiency anemia non-dialysis dependent chronic kidney disease ckd ferric citrate pediatric dialysis
restoration of chronotropic competence in heart failure patients with normal ejection fraction

Conditions: Heart Failure

Summary: this study will look at how pacing your heart may assist your daily activities and how you are feeling.

reset is a multicenter trial that will assess the effect of pacing in heart failure patients with a normal ejection fraction (or diastolic heart failure). the purpose of the reset study is to evaluate the effect of pacing on exercise capacity and quality of life in this heart failure population.

Eligibility criteria:
inclusion criteria: * patients who are in sinus rhythm * patients who are on stable medical therapy * patients who exhibit signs and symptoms of heart failure, new york heart association (nyha) class ii or iii * patients who have experienced a hospitalization for decompensated heart failure; treatment for pulmonary congestion or volume overload; chronic treatment with a loop diuretic; or a brain natriuretic peptide (bnp) \> 125 ng/l. * left ventricular ejection fraction (lvef) ≥ 50% exclusion criteria: * patients with persistent atrial fibrillation or atrial flutter * patients who are in complete heart block * patients who have experienced a recent myocardial infarction (mi) or have unstable angina or require cardiac surgery or other procedures * patients who have severe heart valve disease or valve replacement * patients with a contraindication for a pacemaker system * patients who have a neuromuscular, orthopedic or other non-cardiac condition that prevents patient from exercise testing * patients who have infiltrative or hypertrophic cardiomyopathy * patients who have known severe pulmonary disease * patients with uncontrolled diabetes or blood pressure (systolic blood pressure (sbp) \> 160 mmhg or diastolic blood pressure (dbp) \> 95 mmhg)

Keywords: heart failure exercise capacity ejection fraction heart failure normal ejection fraction
neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as predictors for adverse events in evar

Conditions: Inflammation in EVAR

Summary: this study investigated the association of chronic inflammatory markers with the clinical outcome after endovascular aneurysm repair (evar) for abdominal aortic aneurysm.

the study included 230 consecutive aaa patients, treated electively by evar from march 2016 to february 2019. the values of simple inflammatory markers,neutrophil-lymphocyte ratio (nlr) and platelet-lymphocyte ratio (plr), were measured pre- and postoperatively.adverse events included any major adverse cardiovascular events (mace), acute kidney injury and death from any cause.

Eligibility criteria:
inclusion criteria: * aaa * elective * evar exclusion criteria: * emergency * open surgery
a comparison of propofol based total intravenous anesthesia and desflurane based balanced anesthesia on renal protection during deceased brain dead donor kidney transplantation - a prospective, randomized trial

Conditions: End Stage Renal Disease

Summary: renal ischemia/reperfusion (i/r)-induced injury is known to be associated with immediate and long-term kidney dysfunction after renal transplantation. protecting the kidney against i/r injury and maintaining renal function during renal transplant surgery is therefore very important in order to improve post-operative outcome. this purpose of this study is to investigate whether propofol anesthesia done in both kidney donors and recipients during deceased brain dead donor kidney transplantation is effective in reducing renal i/r injury via its antioxidant and antiinflammatory properties and improve post-transplant outcome compared to desflurane anesthesia.


Eligibility criteria:
inclusion criteria: * adult deceased brain dead kidney donors and recipients scheduled for renal transplantation exclusion criteria: 1. donor exclusion criteria: (1) refusal of legal guardian 2. recipient exclusion criteria: 1. patient refusal 2. hypersensitivity to propofol, soybeans or peanuts 3. history of vitamin c or e intake within 5 days before surgery 4. history of acute myocardial infarct within 6 months before surgery 5. congestive heart failure (nyha iii-iv) 6. autoimmune disease patients 7. bmi over 30 kg/m2 8. left ventricular ejection fraction less than 35% upon preoperative echocardiography

Keywords: propofol, renal protection, kidney transplantation
a multi-omics-based metabolic typing study of gastric cancer

Conditions: Gastric Cancer; Multi-omics; Diagnosis

Summary: in the study, the investigators obtained gastric cancer tissues from 480 gastric cancer patients who had undergone surgery at the zhejiang cancer hospital's biospecimen bank between 2012-2019, and obtained relevant clinical information. the gastric cancer tissues were subjected to transcriptomic, metabolomic and other multi-omics testing, and analyzed for the metabolic changes of gastric cancer, and proposed to discover relevant therapeutic targets.


Eligibility criteria:
inclusion criteria: * 18≤age≤80 * histologically or cytologically confirmed gastric cancer * undergo surgery for radical or palliative gastric cancer (both open and laparoscopic) * patients with survival follow-up information exclusion criteria: * two or more kinds of malignant tumors at the same time * incomplete or missing case information * preoperative diagnosis of residual gastric cancer
treatment of coronary artery disease (cad) with bare metal stent (bms) followed by paclitaxel-coated balloon catheter versus paclitaxel-eluting stent

Conditions: Coronary Artery Disease

Summary: the purpose of this study is to compare the one-time application of paclitaxel from sequent please (paclitaxel-coated balloon catheter) after using the coroflex blue (cobalt chromium stent) with the slow releasing of small dose of paclitaxel from the coroflex please (paclitaxel-eluting stent) stent system in a non-inferiority trial.


Eligibility criteria:
inclusion criteria: * symptomatic coronary artery disease including patients with chronic stable angina, unstable angina and silent ischemia * presence of one or more coronary artery stenosis \>50% in a native coronary artery from 2.25 to 3.5 mm in diameter that can be covered with one stent * one lesion treated with the study device exclusion criteria: * pregnancy * known intolerance to aspirin, clopidogrel, heparin, stainless steel, paclitaxel, cobalt, chromium or contrast material * inability to provide informed consent * currently participating in another trial before reaching the primary endpoint * elective surgery within 12 months of percutaneous coronary intervention (pci) unless dual antiplatelet therapy is maintained throughout the peri-surgical period * acute or recent myocardial infarction * left ventricular ejection fraction (lvef) \< 30 % * stroke or transient ischemic attack within 6 months * stented segment longer than 23 mm * vessel diameter of less than 2,5 mm * significant calcification, chronic total occlusion (cto) or thrombus in the target lesion
continuous glucose monitoring during intecorse in young adults with type 1 diabetes

Conditions: Diabetes Mellitus Type 1

Summary: determine the incidence of hypoglycemia during / after sexual intercourse among young adults with type 1 diabetes using continuous -type sugar meter ipro for a week.

determine the incidence of hypoglycemia during / after sexual intercourse among young adults with type 1 diabetes using continuous -type sugar meter ipro for a week.

Eligibility criteria:
inclusion criteria: type 1 diabetes exclusion criteria: type 2 diabetes other concomitant disease
quantitative mri in assessing disease in patients with brain tumors

Conditions: Tumors Metastatic to Brain; Unspecified Adult Solid Tumor, Protocol Specific

Summary: this pilot clinical trial studies quantitative magnetic resonance imaging (mri) at 3 tesla in assessing disease in patients with tumors that have spread to the brain (brain metastases). in addition to routine care brain imaging of the brain, this study will include advanced multiparametric mri sequences to measure vascular, cellular, and molecular properties of the tumor. performing extra scans during mri provides more information about the metastases and may better predict treatment response.

primary objectives: i. to correlate pre-treatment measures of biophysical parameters in metastases-obtained using advanced, quantitative mri techniques in patients receiving standard-of-care (soc) therapy for 1-4 brain metastases-with treatment-induced changes in lesion size, time-to-progression (ttp), and overall survival (os). outline: patients undergo hybrid 3 tesla mri examination that includes standard mri sequences, diffusion-weighted (dw)-mri, chemical exchange saturation transfer (cest), and combined dynamic contrast enhanced (dce)-mri/dynamic susceptibility contrast (dsc)-mri at baseline.

Eligibility criteria:
inclusion criteria: * patients must sign an institutional review board (irb)-approved informed consent document * patients must have been diagnosed with one of the following: * primary brain tumor (glioma, gbm etc); or * up to 10 brain metastases * patients must have been diagnosed with 1-4 brain metastases * at least one of the brain metastases must measure 5 mm (or more) in short axis diameter in the axial plane * patients must be scheduled to undergo standard brain cancer interventions: * chemotherapy or targeted antiangiogenic therapy, in the case of primary brain tumor; or * stereotaxic radiotherapy (srs) or whole brain radiotherapy (wbrt), in the case of brain metastases. * patients must be scheduled to receive a 3-tesla (3t) mri exam as part of their standard of care (this exam will be modified to also include pulse sequences with are for research only) exclusion criteria: * patients who have received previous treatment (chemotherapy or radiotherapy) for any brain tumor (primary or metastatic). * patients who are scheduled to receive a 1.5t mri exam * patients incapable of giving informed written consent, due to mental disability, altered mental status, confusion, cognitive impairment, or psychiatric disorders. * patients scoring 14.5 or lower on the university of california, san diego brief assessment of capacity to consent (ubacc) questionnaire will not be allowed on the study
the role of paracetamol-caffeine and laser irradiation on controlling pain and discomfort during orthodontic treatment

Conditions: Pain and Discomfort; Orthodontic Appliance Complication

Summary: patients with class i malocclusion who have mild to moderate crowding will be treated in this study. the efficacy of low level laser therapy and panadol-extra® in relieving pain due to orthodontic treatment will be assessed. the effect of these two interventions on oral-health related quality of life during all stages of orthodontic treatment will be explored, i.e. at the following stages: (1) separation between teeth, (2) archwire changing, (3) bonding of brackets, (4) removal of the fixed appliances. there are three groups : 1. a group of patient being irradiated with low-level laser therapy (lllt) at specific time points to relieve pain and discomfort. 2. a group of patient in which pain control will be accomplished by prescribing panadol extra tablets in a regular manner. 3. a group of patients in which nothing will be given to them during the course of treatment.

the assessment of oral-health-related quality of life during the different stages of orthodontic treatment is probably unique in the literature. the study will cover the different stages of orthodontic treatment from a to z. in other words, patients will be followed up till the end of treatment at which fixed appliances are removed. pain control will be accomplished in one arm using lllt and in another arm by prescribing panadol extra®. a third group will be left without any medication or laser irradiation to serve as a control group.

Eligibility criteria:
inclusion criteria: * class i malocclusion with mild to moderate crowding (2-5 mm of tooth-size-arch-length-discrepancy).. * good oral hygiene and periodontal health * no need for any preparation for fixed orthodontic appliance. * no severe skeletal discrepancy (i.e. class i skeletal relationship). exclusion criteria: * previous orthodontic treatment * patients with psychological abnormalities. * patients with systematic diseases or being treated from chronic pain or headache.
trans care: an online intervention to reduce symptoms of gender dysphoria

Conditions: Gender Dysphoria

Summary: the current project aims to improve the well-being of trans and nonbinary (tnb) individuals through an online intervention (trans care) targeting the reduction of symptoms of gender dysphoria. the trans care intervention will involve the creation of an online intervention comprised of eight modules intended to reduce symptoms of gender dysphoria, increase active coping, and improve the well-being of tnb individuals. aim 2 is a randomized controlled trial of the proposed intervention and will enroll 260 tnb participants.

the overall purpose of this project is to create a free intervention that can be disseminated widely throughout tnb communities to improve well-being in an easy, accessible way. development and execution of the trans care intervention involves two primary aims: * aim 1) feasibility and acceptability analysis (faa) \[represented by nct05884307\] * aim 2) a pilot randomized controlled trial (rct) of trans care's efficacy \[represented in this study record\] aim 2 is a rct in which participants' scores of psychological wellbeing and coping strategies in the intervention vs waitlist control group will be analyzed. additionally, participants who drop out of the rct will be asked to complete measures at dropout to determine what dose size of trans care (i.e., how many modules) is necessary to have a significant change in mental well-being. finally, waitlisted participants will be offered the intervention within one month of the completion of data collection. aim 2 hypotheses: * tnb participants who received the trans care intervention will demonstrate improvement on quantitative measures of psychological well-being, gd symptoms, and coping strategies compared to waitlisted individuals. * changes will be maintained at 3 months follow-up indicating that the trans care intervention has a sustained impact on improving tnb individuals' coping. aim 2 endpoints: the primary endpoint of aim 2 will be to determine if participants who engaged the trans care intervention experienced psychological improvement in their mental health as a result of completing the intervention.

Eligibility criteria:
inclusion criteria: * identify as transgender, transsexual, nonbinary, and/or have a transgender history. * experience gender dysphoria. * time available to commit to completing a 4-5-hour online intervention and 1-2 hours to complete follow up surveys exclusion criteria: * under 18 years old * individual does not identify as transgender, transsexual, nonbinary, and/or have a transgender history * does not experience gender dysphoria * is unable to commit to the time requirements of the study * does not have access to an internet compatible device
effects of krill oil on endothelial function in patients with type 2 diabetes mellitus

Conditions: Type II Diabetes Mellitus

Summary: the purpose of this study is to evaluate the effects of krill oil supplementation in patients with type 2 diabetes mellitus on heart health and laboratory diabetic measurements. patients who enroll in this study will be asked to visit the western connecticut health network biomedical research institute on 3 separate occasions: for baseline testing, after 4 weeks of supplementing with krill oil, and after 4 weeks of supplementing with a placebo. patients will be randomized into one of two groups to determine the order in which they receive the supplement and placebo. every patient will receive both the krill oil and the placebo, but both the coordinator and the patient are blinded to which is which. at each visit, participants will undergo a non-invasive test which measures the function of the inner lining of blood vessels and they will also have blood drawn. fasting is required before each appointment. the blood drawn is used to measure their hemoglobin a1c, glucose, hdl, ldl, total cholesterol, c-peptide and total antioxidant capacity. risks to taking krill oil supplements are likely to include bad breath, heartburn, fishy taste, upset stomach, nausea, loose stools, gas, and bloating. risks of endopat testing are not permanent and may include pain, numbness, tingling, redness, and bruising at the site of the blood pressure cuff. risks that are associated with drawing blood may include redness, swelling, pain or discomfort, bruising at the site of the needle stick, or in very rare cases, infection at the needle site. to minimize these risks, trained technologists and phlebotomists will be used for all procedures. this is not a treatment option; while involved in this study all participants will continue their regular treatment for type 2 diabetes mellitus (as well as any other applicable conditions).


Eligibility criteria:
inclusion criteria: * clinical diagnosis of type 2 diabetes mellitus * stable on glucose lowering agents exclusion criteria: * age of less than 18 * currently pregnant or lactating * blood coagulation disorder or taking oral anticoagulants other than aspirin * seafood allergy * presently taking fish oil or krill oil supplements

Keywords: krill oil endothelial function type ii diabetes mellitus